Use of azithromycin in the treatment of acute exacerbations of COPD by Milstone, Aaron P
© 2008 Dove Medical Press Limited.   All rights reserved
International Journal of COPD 2008:3(4) 515–520 515
REVIEW
Use of azithromycin in the treatment
of acute exacerbations of COPD
Aaron P Milstone
Division of Allergy, Pulmonary 
and Critical Care, Vanderbilt 
University Medical Center, 
Nashville, TN, USA
Correspondence: Aaron Milstone
Vanderbilt University Medical Center, 913 
Oxford House, Nashville, TN 37232, USA
Tel +1 615 936 0393
Fax +1 615 936 0396
Email aaron.milstone@vanderbilt.edu
Abstract: Chronic bronchitis is a relatively common entity among patients with underlying 
chronic obstructive lung disease. Typical treatment includes pulmonary hygiene, bronchodilators, 
and antimicrobial therapy. In recent years, the duration of antimicrobial therapy in acute 
exacerbations of COPD has become shorter and shorter. This review summarizes the data on 
the use of the drug azithromycin for this particular patient population with a focus on 3-day 
and single-day therapy. 
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Background
Millions of people in the US suffer from chronic obstructive pulmonary disease and 
the prevalence of chronic bronchitis estimated to be greater than 3% (Soriano et al 
2003). Patients with chronic bronchitis may experience exacerbations (AECBs) of 
their lung disease with typical complaints of increased dyspnea, productive cough 
and purulent sputum (Anthonisen et al 1987). Treatment of all types of exacerbations 
with antimicrobial agents remains debated but a recent meta-analysis by Saint et al 
(1995) conﬁ  rmed the need for antibacterial treatment in the most severe cases of 
AECB (Type 1). About 50% of patients with chronic bronchitis will have at least 
2 exacerbations per year (DeAbate et al 2000; Kreis et al 2000), with 20% of these 
episodes resulting in hospitalizations (Kreis et al 2000). About half of all patients 
discharged from the hospital for treatment of the exacerbation are readmitted more than 
once within the following 6 months (Snow et al 2001). It also appears that frequent 
AECBs can be associated with a more fulminate decline in FEV1 compared to patients 
without exacerbations (Kanner et al 2001; Donaldson et al 2002). Thus, effective 
treatment of the AECB and consideration for prevention of AECB are major goals in 
the care of patients with chronic obstructive lung disease.
Since its introduction into the US antibiotic market in 1991, azithromycin has had 
multiple indications and formulations (Drug Details 2006). As a 5-day course (5-day 
formulation; Zpack  ®) the drug was indicated for the treatment of adults with mild 
to moderate community acquired pneumonia (CAP), acute exacerbations of chronic 
bronchitis (AECB) and acute bacterial sinusitis (ABS). Additionally, a 3-day formula 
(TriPak  ®) and a single dose (Zmax  ®) have been made available in the US in recent 
years. The 3-day dosing is indicated for both AECB and ABS whereas the single dose 
does not currently carry a US FDA indication for the treatment of AECB. These shorter 
courses of the drug were used in Europe and elsewhere in the world since the early 
1990s. Today, these products are available as generics and it is unlikely that future 
re-formulations of azithromycin will be added to the antibiotic market. This review 
will evaluate the use of azithromycin in its various formulations for the treatment and 
prevention of acute exacerbations of COPD.International Journal of COPD 2008:3(4) 516
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Zpack  ® – 5-day formulation
The 5-day formulation of azithromycin was the original for-
mulation introduced in the US. At the time of its introduction 
most acute exacerbations of chronic bronchitis were treated 
with antimicrobial agents such as tetracyclines, beta lactams, 
and sulfa drugs. Early trials found that the 5-day formula-
tion of this macrolide was well tolerated and efﬁ  cacious 
(Dark 1993; Whitlock 1995). Further, Destache et al (1999) 
showed in a retrospective study that newer agents, including 
azithromycin, significantly impacted AECB in terms of 
decreased hospitalization rates, longer time between AECB 
episodes and lower total cost for treatment of the exacerbation. 
More recent studies have focused on respiratory ﬂ  uorquino-
lones as the major comparator to Zpack®. Recent studies by 
DeAbate et al (2000) and Amsden et al (2003) have shown that 
macrolide antibiotics maintain very good clinical and bacte-
riological cure rates compared to quinolones. In the Amsden 
study, levoﬂ  oxacin was used as a comparator and early cure 
rates were similar in both arms. Early cure rates were similar 
between both antibiotics; 89% of azithromycin-treated patients 
and 92% of levoﬂ  oxacin-treated patients (p = 0.22). The test of 
cure in this study (day 24) again showed no signiﬁ  cant differ-
ence between the favorable response rates for the two treatment 
groups (82% vs 86%, respectively; p = 0.53). Bacteriological 
eradication rates did not differ for the two agents when Hae-
mophilus inﬂ  uenza, Streptococcus pneumonia, and Mycobac-
terium catarrhalis were cultured and evaluated. Interestingly, 
over half of all enrolled patients in both arms of the study were 
active smokers but all enrolled patients had to have FEV1 35% 
(during exacerbation free testing periods). DeAbate et al (2000) 
evaluated 5-day azithromycin versus a similar duration of the 
ﬂ  uroquinolone, moxiﬂ  oxacin. The study population in this 
study included adults with chronic bronchitis. No mention 
of FEV1 was given in this study and like the Amsden study, 
approximately 50% of patients in both antibiotic arms were 
active smokers. Early clinical cure rates were not signiﬁ  cantly 
different; azithromycin 92% and moxiﬂ  oxacin 91%. The 
clinical success of the drugs was maintained to the test of cure 
(days 14–21 post therapy). Microbiological success was very 
good for both agents although there was a difference between 
the two drugs for Haemophilus parainﬂ  uenzae (azithromycin 
62%, moxiﬂ  oxacin 88%). One study has compared azithromy-
cin efﬁ  cacy to another macrolide, dirithromycin. In this ﬁ  ve 
center study, investigators found that clinical success was not 
statistically different between the two drugs early (Day 7) or 
late (Day 30). A summary of the major studies comparing the 
5-day formulation of azithromycin to various comparators is 
shown in Table 1.
TriPak® – 3-day formulation
In more recent years, azithromycin has been available as a 
3-day formulation in the US. The 3-day formulation has a 
number of advantages over the 5-day formulation of the drug. 
First compliance is virtually assured with such a short course 
of antibiotic therapy. In addition, pharmacokinetic studies have 
shown that the serum and granulocyte drug concentrations are 
signiﬁ  cant different between the two dosing methods (Amsden 
et al 1999). Table 2 shows 11 various studies comparing 
the 3-day formulation with various comparators including 
amoxicillin, amoxicillin-clavulanate, and other macrolides. 
The efﬁ  cacy of the 3-day formulation has ranged between 
67.6 and 100% for patients cured or improved from AECB at 
early study time points (12 days). Late efﬁ  cacy (or test of 
cure) is maintained at levels between 77% and 96%. In all of 
these studies the 3-day formulation is generally well tolerated 
with only a minimal increase in gastrointestinal side effects 
compared with the 5-day formulation.
Although not shown on Table 2, one study has evaluated 
the clinical efﬁ  cacy of the 3-day formulation in patients 
with very severe COPD (Cazzola et al 2005). This study by 
Table 1 Clinical response rates (percent cured and improved) for azithromycin (5-day formulation) versus various comparator(s) 
at early and late time points
Study Year Comparator Azithromycin 
5-day formulation 
Various comparators  Deﬁ  nition of chronic 
bronchitis
Early Late Early Late
Dark 1993 Cefaclor 100.0 NS 92.0 NS NS
Whitlock 1995 Amoxicillin-
clavulanate
100 90.0 93.0 85.0 ATS
DeAbate et al 2000 Moxiﬂ  oxacin 92.0 88.0 91.0 88.0 ATS
Amsden et al 2003 Levoﬂ  oxacin 88.9 81.9 92.4 85.6 ATS
Castaldo et al 2003 Dirithromycin 75.7 86.5 84.8 95.5 ATS
Abbreviations: ATS,  American Thoracic Society; NS, not stated.International Journal of COPD 2008:3(4) 517
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Cazzola et al revealed that 17/21(81%) episodes of acute 
exacerbations in 65 adult COPD patients were either cured 
or improved at an early time point (3–5 days post therapy). 
Patients enrolled in this study had severe to very severe 
lung disease based on American Thoracic Society criteria 
and had all received the 23-valent pneumococcal capsular 
polysaccharide vaccine. Bacteria isolated from the sputum 
of patients with acute exacerbations showed a variety of 
pathogens including gram negative bacteria and S. aureus. 
No S. pneumoniae was isolated from the sputum of patients 
enrolled in this study who had acute exacerbations of their 
COPD. The main impact of this type of study is that it is more 
typical of a “real world” scenario; one where most patients 
with advanced COPD/AECB have received vaccination 
against pneumococcus. Other groups have attempted to 
simulate more real world scenarios and gauge AECB 
outcomes not just on pure clinical or bacteriological criteria 
but to also use health related quality of life (Grossman et al 
1998; Milstone et al 2005; Spencer and Jones 2003). One of 
these observational studies, was a prospective, multicenter, 
observational study evaluating outpatient adults with AECB 
who received either 3 days of AZM 500 mg/d or 5– to 14-day 
courses of standard antibiotics (usual care) as directed by a 
clinician (Milstone et al 2005). Patients with AECB treated 
with a 3-day course of azithromycin experienced signiﬁ  cant 
improvements in health related quality of life as measured by 
a clinical important difference on the St. George’s respiratory 
questionnaire and the SF-36 compared with baseline.
An additional area of interest with the 3-day formu-
lation of azithromycin is the paradox between in vitro 
antibiotic resistance and in vivo success. Most antibiotic 
resistance surveillance programs have demonstrated substantial 
resistance rates for S. pneumoniae and H. inﬂ  uenzae to the 
macrolide class of antibiotics (Doern et al 2001; Low et al 2002; 
Jacobs 2003; Powis et al 2004; Low 2004). Despite these 
bacteriological trends, clinical response to macrolide therapy 
remains adequate (as indicated by the late clinical cure 
rates shown in Table 2 – range 77%–96%). Two suggested 
mechanisms for the paradox between the “petri” dish and the 
patient exist in the literature. One is the high rate of efﬂ  ux 
mediated (mef type) resistance among North American 
isolates of pneumococcus (Lantero et al 1998) in contrast 
to Europe where most macrolide resistance is methylation 
mediated (erm type). This type of bacterial resistance can be 
overcome by increasing drug concentration in serum or white 
blood cells. The second factor in this disparity is that pharma-
codynamic differences among the macrolide class at the site 
of infection plays a critical role in predicting clinical success. 
Classic macrolides such as erythromycin are time dependent, 
ie, the amount of time the drug concentration is above the 
MIC for the organism determines optimal activity. In contrast, 
for the azalide, azithromycin, optimal activity is dependent 
on maximizing the area under the concentration-time 
above the MIC curve (AUIC) (Craig 1997). The dosing 
regimens of these agents are designed to maximize these 
pharmacodynamic parameters. Foulds et al (1990) have 
Table 2 Clinical response rates (percent cured and improved) for azithromycin (3-day formulation) versus various comparator(s) at 
early and late time points
Study Year Comparator Azithromycin
3-day formulation 
Various comparators  Deﬁ  nition of 
chronic bronchitis
Early Late Early Late
Mertens et al 1992 amoxicillin 100.0 96.0 92.0 80.0 ATS
Bradbury 1993 clarithromycin 95.0 NS 97.0 NS NS
Beghi et al 1995 amoxicillin-clavulanate 67.6 NS 97.3 NS NS
Biebuyck 1996 amoxicillin-clavulanate 92.1 95.7 86.4 79.6 ATS
Gris 1996 amoxicillin-clavulanate 86.0 NS 92.0 NS ATS
Zachariah 1996 amoxicillin-clavulanate 94.0 NS 93.0 NS ATS
Laurent 1996 roxithromycin NS 91.2 88.8 NS NS
Hoepelman et al 1997 amoxicillin-clavulanate 95.0 77.0 90.0 66.0 ATS
Cazzola et al 1999 dirithromycin 92.5 89.2 90.0 94.4 ATS
Schouenborg et al 2000 pivampicillin 93.0 78.0 86.0 81.0 ATS
Swanson et al 2005 clarithromycin 93.0 85.0 94.0 82.0 ATS
Zervos et al 2007 moxiﬂ  oxacin 93.0 89.0 84.0 73.0 Anthonisen et al 
1987
Abbreviations: ATS,  American Thoracic Society; NS, not stated.International Journal of COPD 2008:3(4) 518
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showed that tissue concentrations were above the MIC90 
for all relevant community-acquired respiratory pathogens, 
including pneumococci, for at least 8 days after a single 500 
mg oral dose of azithromycin (Foulds et al 1990). Thus, the 
combined effects of overcoming efﬂ  ux mediated resistance 
with the unique pharmacodynamic properties of azithromycin 
make it difﬁ  cult to rely on standard in vitro assessments 
of bacteriologic susceptibility. The most current bacterial 
resistance/surveillance studies have started to assess the 
prevalence of the various mechanisms of macrolide resistance 
(ie, efﬂ  ux versus methylation) (Farrell, 1996). However, few 
studies on macrolide resistance evaluate each individual 
macrolide thus ignoring the potential pharmacodynamic 
differences of each drug in this class.
Zmax® – 1-day formulation
A single dose preparation of azithromycin is now also 
available for utilization in the treatment of respiratory 
infections. In 2005, the US FDA approved this formulation 
of the drug for both acute bacterial sinusitis and community 
acquired pneumonia in adults. The drug is given as a single 
2-g dose and the drug is released into the gastrointestinal tract 
using microsphere technology to minimize side effects (Zmax 
package insert). Serum and white blood cell concentrations 
of the 2-g/1-day formulation are substantially higher than 
the 3-day formulation of azithromycin (Liu et al 2007). 
Theoretically, this early peak effect (ﬁ  rst 24 hours) may be 
beneﬁ  cial to the patient as bacterial burden is likely highest 
in the first days of treatment of an acute exacerbation. 
A single study has now been published which evaluates the 
efﬁ  cacy of a 1-day formulation for the treatment of AECB 
(Zeros et al 2005). The comparator in this study is oral 
levoﬂ  oxacin which is given for 7 days. In this double-blind, 
double dummy study comparable clinical cure agents for 
the two antibiotics were seen late (Days 14–21; 93.6% for 
azithromycin and 92.7% for levoﬂ  oxacin). Even in cases of 
very severe airﬂ  ow obstruction (FEV1 30%), azithromycin 
success rates were high (88%).
Azithromycin and prophylaxis
for AECB
Data are limited about prophylaxis with azithromycin for 
exacerbations of chronic bronchitis. However, the drug has been 
used as a prophylactic agent in the cystic ﬁ  brosis population 
to reduce the risk of respiratory exacerbations with moderate 
success (Wolter et al 2002; Saiman et al 2003; Equi et al 2002). 
There have also been at least two trials in patients with obstructive 
lung disease due to bronchiectasis (Davies and Wilson 2004). 
In one study conducted at the Royal Brompton, London, UK, 
infectious exacerbations decreased from a mean of 0.71 per 
month to 0.13 per month (p  0.001) in 33 patients on 4 months 
of drug prophylaxis (12 days continuous therapy followed by 
250 mg on Mondays, Wednesdays, and Fridays). An additional 
study in bronchiectasis utilized twice weekly azithromycin 
(500 mg dose) for a period of 6 months (Cymbala et al 2005). 
Exacerbation incidence and sputum volume measurements 
were compared from baseline to the end of the study. Among 
the eleven patients analyzed in this study azithromycin signiﬁ  -
cantly decreased the incidence of exacerbations compared with 
usual medications (5 vs 16; p = 0.019). Mean sputum volume 
over a 24-hour 1 period also decreased by approximately 15% 
(p = 0.005). However, one small European study does suggest 
a beneﬁ  t to treating patients with COPD with 500 mg/day for 
3 days every 3 weeks (Gomez et al 2000). This study evaluated 
54 patients with moderate COPD who were treated during a 
single winter season. Both hospital admissions and the number 
of acute infectious exacerbations of COPD were statistically 
decreased in the azithromycin arm of the study compared to a 
non-treated control group.
Theoretically, it is possible that the efficacy of 
azithromycin in these different patient populations (cystic 
ﬁ  brosis and bronchiectasis) may be more related to its 
immunomodulatory effect rather than its antimicrobial 
effect. Azithromycin and the other macrolides can decrease 
neutrophil chemotaxis and inﬁ  ltration into the respiratory 
epithelium, downregulate adhension molecule expression 
and enhance neutrophil apoptosis (Koch et al 2000; Amsden 
2005). All of these factors may play signiﬁ  cant roles in 
exacerbations of COPD. To this end, the National Heart, 
Lung, and Blood Institute and the COPD Clinical Research 
Network is currently enrolling patients in a multi-center 
investigation to determine if azithromycin decreases the 
rate of exacerbations over a 1-year time period (Clinical 
trials 2007). In this prospective, randomized, double-blind, 
placebo-controlled study over 1,000 patients with at least 
moderately severe COPD will be enrolled. Secondary 
endpoints will include measures of quality of life, the 
incidence of macrolide-resistant bacterial colonization 
and cost-effectiveness. Optimistically, this type of trial 
design will help to deﬁ  nitively determine if prophylactic 
macrolide therapy can prevent or delay the time between 
COPD exacerbations.
Conclusion
Azithromycin is a available in three major formulations (1-day, 
3-day, and 5-day). All three have had signiﬁ  cant success in International Journal of COPD 2008:3(4) 519
Azithromycin for acute COPD exacerbations
AECB trials against a wide variety of comparators. Given rising 
concern about bacterial resistance; the higher strength prepa-
rations of azithromycin prescribed over a shorter duration of 
time offer considerable pharmacodynamic advantages. Future 
studies will assist in determining the efﬁ  cacy of this drug in 
the prevention of exacerbations of chronic bronchitis.
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